Cat. No. ARG43877
The GDF15 Knockout MDA-MB-231 Cell Line is a CRISPR/Cas9-edited breast cancer cell line lacking growth differentiation factor 15. MDA-MB-231 is a triple-negative, highly invasive adenocarcinoma line. GDF15 is a stress-responsive cytokine that signals through the GFRAL-RET complex to activate MAPK/ERK and PI3K/AKT pathways. Researchers can use this model to investigate GDF15-dependent proliferation, migration, invasion, drug resistance, and metabolic regulation in triple-negative breast cancer. It supports signaling studies, functional assays such as Transwell migration and Annexin V apoptosis assays, and in vivo xenograft or drug screening applications.
| Host Cell | MDA-MB-231 |
| Sex of Donor | Female |
| Age | 51 years |
| Gene Name | Gdf15 |
| Gene Identifier | NCBI Gene ID 9518 |
| Morphology | Epithelial-like |
| Growth Mode | Adherent |
| Storage | Liquid nitrogen (LN2) |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | The bacterial, yeast, and fungi are not detected in these cells by daily monitor. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The GDF15 Knockout MDA-MB-231 Cell Line is a CRISPR/Cas9-edited knockout cell line in which the GDF15 gene encoding growth differentiation factor 15 has been disrupted. This stable loss-of-function model is derived from the MDA-MB-231 parental line, ensuring isogenic experimental controls for studying GDF15-dependent processes.
MDA-MB-231 is a human epithelial cell line isolated from the pleural effusion of a metastatic breast adenocarcinoma patient. It displays a triple-negative phenotype, lacking ER, PR, and HER2 expression, and is characterized by high invasiveness and tumorigenicity. This line serves as a standard model for aggressive, mesenchymal-like triple-negative breast cancer (TNBC) and is extensively used to investigate metastatic progression and drug resistance.
GDF15 is a stress-responsive member of the TGF-?? superfamily that functions as a secreted cytokine. Its transcription is upregulated by diverse stressors, with key transcription factors such as p53, NF-??B, EGR1, ATF4, and CHOP mediating induction, often in concert with inflammatory signals like IL-1?? and TNF-??. Secreted GDF15 specifically binds to the GFRAL receptor, which then recruits the RET co-receptor to initiate intracellular signaling. This ligand?Creceptor complex activates the RAS-RAF-MEK-ERK kinase cascade and the PI3K-AKT pathway, and also modulates SMAD2/3 and NF-??B activity. Consequently, GDF15 exerts control over cellular apoptosis, metabolic adaptation, and inflammatory responses.
Disruption of GDF15 in the MDA-MB-231 background ablates GDF15-GFRAL-RET-dependent signaling, yielding a precise loss-of-function tool for TNBC research. Without GDF15, the cells no longer activate downstream MAPK/ERK and PI3K/AKT pathways, enabling clear assignment of phenotypes to GDF15 function. This knockout model is particularly valuable for probing GDF15’s contributions to aggressive features of triple-negative breast cancer, including enhanced proliferation, migratory capacity, invasion, and resistance to chemotherapeutic agents. It also facilitates study of GDF15-driven metabolic changes and its paracrine effects in the tumor microenvironment.
Typical experimental applications include Western blot analysis of phosphorylated ERK and AKT, RT-qPCR profiling of downstream target genes, and cell proliferation assays to quantify GDF15-dependent growth. Transwell migration and invasion assays, coupled with Annexin V apoptosis assays, provide functional readouts of motility and cell death, while RNA-sequencing reveals transcriptome-wide changes. For in vivo analysis, xenograft tumor growth studies allow assessment of GDF15’s role in tumor formation and progression. Additionally, this cell line is well-suited for high-throughput screening of inhibitors or antibodies targeting the GDF15-GFRAL signaling axis. For further information or to discuss customized project needs, please contact Ascent Research.
